2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4545 Empowering multiple myeloma patients through peer support: A cross-sectional analysis of peer coaching efficacy and engagement timing

Jay R Hydren, PhD, Cheri Marmarosh, PhD2, Rozalynn Hite, OTR/L3, María F. Sahagún Sánchez, MS4, Jennifer M Ahlstrom, BA5, Jorge Arturo Hurtado Martinez, MD, MHSc6, Japneet K Oberoi, MBBS7, Gurbakhash Kaur, MD,MA8, Nadine Abdallah I, MD9
1 HealthTree Foundation, South Jordan, Utah, United States
2 George Washington University, Washington DC, District of Columbia, United States
3 HealthTree Foundation, South Jordan, Utah, United States
4 HealthTree Foundation, South Jordan, Utah, United States
5 HealthTree Foundation, South Jordan, Utah, United States
6 HealthTree Foundation, South Jordan, Utah, United States
7 University of South Dakota, Vermillion, South Dakota, United States
8 The Mount Sinai Hospital, New York, New York, United States
9 Mayo Clinic, Rochester, Minnesota, United States

Background: Multiple myeloma (MM) patients face complex treatment decisions, emotional distress, and information overload at diagnosis and throughout their disease course. While peer support groups are available, 1-on-1 peer coaching provides personalized guidance that better addresses individual patient needs. The HealthTree Coach Program connects patients with peer coaches—experienced survivors with MM or plasma cell precursor conditions who completed HealthTree Coach Training. However, the optimal timing of coaching engagement and its impact on patient-reported outcomes remain unclear. 

Methods: We conducted a cross-sectional survey study of HealthTree Foundation members between May 2025 and June 2026. The mixed-format questionnaire assessed program awareness, coaching timing relative to the cancer journey, motivations, perceived benefits, selection criteria, communication preferences, well-being, treatment navigation impact, and participation recommendations. 

Results: A total of 62 participants completed the survey. The survey cohort was predominantly female (66.7%) and non-Hispanic (88.9%), with participants aged <50 (3.2%), 50–59 (20.6%), 60–69 (36.5%), and ≥70 (38.1%); 84.1% held a college or graduate degree.

Among respondents, 92.1% (n=58) were aware of the HealthTree Coach Program; 43 (68%) detailed their experience with the program.

Patients’ primary motivations for seeking coaching included help with side effect management (65.4% rated highest importance), learning about treatment experiences (55.6%), connecting with someone outside their family/friends circle (55.6%), understanding lab results (46.2%), preparing for clinical visits (37.7%), and making the best use of doctor time (37.7%). Participants also sought guidance on clinical trials (60.7%), care team assembly (50.0%), financial navigation (48.4%), and specialist selection (40.3%).

Among these 43 participants who engaged in 1-on-1 peer coaching, the most common entry points were during initial MM treatment (34.9%), at precursor disease diagnosis (27.9%), and during remission after first treatment (25.6%). Participants reported engaging in a median of 5 (IQR: 3–12) coaching sessions.

When evaluating coach characteristics, patients rated listening ability (72.6%), authenticity or being a "straight shooter" (73.0%), and emotional supportiveness (49.2%) as "very important". 

Among patients evaluating program impact, 73.8% reported improved overall well-being and reduced anxiety, 61.0% improved coping skills, and 60.0% noted that the program helped with critical treatment decisions. 

Communication preferences included phone calls (65.1%) and video conferencing (30.2%). Additionally, the program proved the efficacy of a virtual model with high impact and low burden: 82.5% of respondents rated in-person meetings as “not important,” demonstrating that remote delivery successfully eliminates geographic barriers. 

Program satisfaction was high: 93% of participants said they would recommend the program to other patients, and 90.7% would choose to have a coach again, with 46.5% indicating they would participate again but would start earlier in their cancer journey—three out of four participants who started after MM treatment would have engaged with a coach sooner. This finding suggests that the optimal starting point for peer-to-peer mentoring for MM patients is at diagnosis while treatment options are still being considered.

Conclusion: One-on-one peer coaching fills critical psychosocial and experiential knowledge gaps that standard clinic visits may not adequately address, providing a clinically impactful complement to current care models.  As blood cancer treatments become more complex and personalized, the need for support from peers who have “been there” will continue to intensify. The finding that nearly half of participants would have preferred to start coaching earlier—ideally at diagnosis—suggests proactive outreach could maximize program impact.  These data documents the impact of an established 1-on-1 peer coaching program on patient survivorship factors alongside treatment, diagnostic understanding, and decision-making, and how patients already considered it as a part of their comprehensive myeloma care. Therefore healthcare systems and patient advocacy organizations should consider integrating and evaluating structured 1-on-1 peer coaching programs into standard care pathways.

Jay R Hydren, PhD: Johnson & Johnson - Research Funding; BioLinRx - Research Funding; Gamida-Cell - Research Funding; Bristol Myers Squibb - Research Funding; Regeneron - Research Funding; Takeda Oncology - Research Funding; Sanofi - Research Funding